Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06730204 | Standardized Nutritional Management of Pediatric Patients With Solid Tumors | recruiting | N/A | 400 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07475182 | Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05364086 |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study(DiRECT) |
| active not recruiting |
| — |
| 2,100 |
| University of Rochester NCORP Research BaseOTHER |
| 1 |
| Mar 13, 2026 |
| clinicaltrials |
| NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | terminated | Phase 1 | 99 | BeiGeneINDUSTRY | 5 | Mar 13, 2026 | clinicaltrials |
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | recruiting | Phase 2 | 88 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT07192315 | Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)(PREDICTO) | not yet recruiting | N/A | 160 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04261413 | Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 16 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.INDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06367751 | Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)(LIQPLAT) | active not recruiting | N/A | 159 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07018622 | Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity(DAPA-ARMOR) | recruiting | Phase 2 | 46 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07464457 | Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors(NEOPRO-SIT) | recruiting | N/A | 125 | Priv.-Doz. Dr. med. Philipp LenzOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05735366 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Chugai PharmaceuticalINDUSTRY | 2 | Mar 10, 2026 | clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07450560 | Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET | active not recruiting | — | 30 | Shuanghu YuanOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07459920 | Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden(CAPTURE) | not yet recruiting | Phase 2 | 156 | National Cancer Institute, NaplesOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462442 | Study of QLS5308 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 192 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 10, 2026 | clinicaltrials |
| NCT04723810 | TumorGlow Intraoperative Molecular Imaging (IMI) | recruiting | Phase 1 / Phase 2 | 500 | University of PennsylvaniaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07069062 | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 261 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04695327 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy(TUNIMO) | completed | Phase 1 | 32 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04912687 | Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients(CIRCULAR) | completed | N/A | 581 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT05661201 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | recruiting | Phase 1 | 24 | Georgetown UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06340815 | Varian ProBeam Proton Therapy System Clinical Trial (Shandong) | completed | N/A | 47 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT02474160 | Collection and Storage of Tissue and Blood Samples From Patients With Cancer | recruiting | — | 5,000 | National Cancer Institute LAOUNKNOWN | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03832569 | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | active not recruiting | Early Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06667960 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 255 | Salubris Biotherapeutics IncINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02617277 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05166694 | Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions | recruiting | N/A | 1,300 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06424665 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07450352 | SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors | not yet recruiting | Phase 2 | 150 | Li MinOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06881108 | Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors(FinFit Aim 1) | completed | — | 16 | Wake Forest University Health SciencesOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07028281 | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 120 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07304128 | A Study of PLB-002 in Advanced Solid Tumors | recruiting | Phase 1 | 100 | Primelink BioTherapeitics(ShenZhen) LimitedINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446816 | A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 | recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 16, 2026source: clinicaltrials